Pancreas Cancer Specialized Program of Research Excelle*

Excelle 胰腺癌专门研究计划*

基本信息

批准号：
7247994
负责人：
Anton Wellstein
金额：
$ 20.97万
依托单位：
GEORGETOWN UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2003
资助国家：
美国
起止时间：
2003-09-30 至 2008-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7247994
关键词：
Address Apoptosis Basic Science Biology Caring Cell Communication Cells Clinical Clinical Research Clinical Treatment Collaborations Databases Detection Development Diagnosis Disease Early Diagnosis Endothelium Excision Funding German population Goals Growth Factor Health system Healthcare Systems Heparin Binding Growth Factor Hospitals Institution Knowledge Life Liquid substance Malignant - descriptor Malignant Neoplasms Malignant neoplasm of pancreas Methods Mitogen-Activated Protein Kinases Modeling Molecular Molecular Target NCOA3 gene Neoplasm Metastasis Nerve Block Neuregulins Neurons Nuclear Receptors Pancreas Pathway interactions Patient Outcomes Assessments Patients Phase I Clinical Trials Radiation Reproduction spores Research Research Infrastructure Research Institute Research Personnel Resources Role Serum Signal Transduction Specialized Program of Research Excellence System Tissues Translating Translational Research Tumor Bank Universities cancer cell career design inhibitor/antagonist killings neoplastic cell novel novel strategies pancreatic neoplasm pleiotrophin programs

项目摘要

The goal of this Specialized Program of Research Excellence (SPORE) in pancreas cancer is to translate outstanding hypothesis-driven basic research into clinical treatment that saves lives. Pancreatic cancer is a devastating cancer that kills patients not just because it may be extremely aggressive but also because it is diagnosed late. This SPORE is a unique collaboration between Georgetown University, Geisinger Health System and INDIVUMED a German Research Institute with a German hospital consortium that brings together an outstanding academic institution, a large regional healthcare system and a German basic and clinical research system to address the biology of pancreatic cancer and clinical care. Project 1 focuses on inhibition of pleiotrophin, a novel heparin-binding growth factor that promotes invasion and metastasis in pancreatic cancer. Project 2 focuses on the role of neuregulins and pleiotrophin in an established model of neuron:tumor cell interaction with the goal of developing methods to block neural invasion by malignant pancreas cells that may ultimately aid in disease palliation. Project 3 focuses on recent findings that inhibition of the nuclear receptor coactivator AIB1 within pancreas cancer cells and adjacent endothelium may block signaling from multiple growth factors to enhance apoptosis. The activation of the ras/MAP kinase pathway that occurs in up to 90% of pancreas cancer is the focus for novel approaches to radiation sensitization in Proiect 4. Investigators at Georgetown have developed a rafl antisense inhibitor that is already in Phase I trial and have developed other molecular targets in the pathway that are complementary. In addition, this SPORE is developing the infrastructure and resources to acquire tissues and bodily fluids from patients (Pancreatic Tumor Bank and Serum Detection & Molecular Identification Cores) with an expected 120 curative resections a year. The SPORE will utilize a biostatistical core to insure that all projects have appropriate designs, methods of analysis, and an integrated database for reporting patient outcomes. Further, the SPORE will support developmental projects designed to generate new knowledge and approaches to early detection and promote the development of career tracks dedicated to translational research in pancreatic cancer. This SPORE is also establishing interactions with SPOREs in other institutions as well as with other NCI- and NIH-funded programs to promote the aggressive development of novel therapies for the control of pancreas cancer

胰腺癌专业卓越研究计划 (SPORE) 的目标是将杰出的假设驱动基础研究可挽救生命的临床治疗。胰腺癌是一种毁灭性的癌症会杀死患者，不仅因为它可能极具侵袭性，还因为它诊断已晚。该 SPORE 是乔治城大学、Geisinger Health 之间的独特合作 System 和 INDIVUMED 是一家德国研究所，与一家德国医院联盟合作，带来了杰出的学术机构、庞大的地区医疗保健系统以及德国的基础和解决胰腺癌生物学和临床护理问题的临床研究系统。项目1重点关注抑制多效素，一种新型肝素结合生长因子，可促进侵袭和转移胰腺癌。项目 2 重点研究神经调节蛋白和多效蛋白在已建立的模型中的作用神经元：肿瘤细胞相互作用，目标是开发阻止恶性细胞侵袭神经的方法胰腺细胞最终可能有助于缓解疾病。项目 3 重点关注最近的发现抑制胰腺癌细胞和邻近内皮细胞内的核受体共激活剂 AIB1 可能会阻断多种生长因子的信号传导以增强细胞凋亡。 ras/MAP 激酶的激活高达 90% 的胰腺癌中发生的途径是新放射治疗方法的焦点项目 4 中的致敏作用。乔治敦大学的研究人员开发了一种 rafl 反义抑制剂，已经处于第一阶段试验，并开发了该途径中的其他互补分子靶标。此外，这个孢子正在开发基础设施和资源来获取组织和体液来自患者（胰腺肿瘤库和血清检测和分子鉴定核心）预计每年 120 例根治性切除手术。 SPORE 将利用生物统计核心来确保所有项目有适当的设计、分析方法和用于报告患者的综合数据库结果。此外，SPORE 将支持旨在产生新知识的开发项目以及早期发现和促进致力于转化的职业轨道发展的方法胰腺癌研究。该孢子还与其他地方的孢子建立了互动机构以及其他 NCI 和 NIH 资助的项目，以促进积极发展控制胰腺癌的新疗法